MED12 and lymphangioma: Whole genome sequencing has elucidated the genetic foundation of ULM, revealing that over 70% of leiomyoma (LM) cases harbor mutations in the mediator complex subunit 12 (MED12), with mutation rates positively correlating with tumor quantity.